
|Videos|April 20, 2021
CAR T Therapy and Durable Responses in MCL
Author(s)Frederick L. Locke, MD
Frederick Locke, MD, discusses treatment options for patients with mantle cell lymphoma and the use of CAR T-cell therapy in clinics.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5






































